Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001274173-25-000298
Filing Date
2025-11-14
Accepted
2025-11-14 12:07:05
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7648
  Complete submission text file 0001274173-25-000298.txt   9569
Mailing Address 201 BISHOPSGATE LONDON X0 EC2M 3AE
Business Address 201 BISHOPSGATE LONDON X0 EC2M 3AE 442078181818
JANUS HENDERSON GROUP PLC (Filed by) CIK: 0001274173 (see all company filings)

EIN.: 000000000 | State of Incorp.: Y9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6282 Investment Advice
(CF Office: 02 Finance)

Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Subject) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91047 | Film No.: 251483252
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)